GlassScriptPhysician profile
Ingrid P Warmuth
NPI 1811942717
$2,874.80
in general payments reported to CMS, 2019-2025
29 companies · $463 in 2025
The $463 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $79.65 · 2021: $42.95 · 2022: $253 · 2023: $485 · 2024: $768 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.85 | 2021-2025 | Rinvoq |
| Novartis Pharmaceuticals Corporation | $491.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $379.70 | 2022-2025 | Sotyktu, Opdivo |
| Allergan, INC. | $182.28 | 2019 | |
| Merz North America, INC. | $171.04 | 2019 | |
| Pfizer INC. | $128.26 | 2019-2024 | |
| Lilly USA, LLC | $96.51 | 2019-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $89.98 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $81.84 | 2022-2024 | Dupixent |
| Leo Pharma INC. | $75.15 | 2019-2024 | Adbry |
| Encore Dermatology INC. | $66.62 | 2019 | |
| Arcutis Biotherapeutics, INC. | $65.17 | 2023-2024 | Zoryve |
| Amgen INC. | $49.13 | 2023-2024 | Otezla |
| Janssen Biotech, INC. | $47.69 | 2022-2025 | Tremfya |
| Epi Health, LLC | $39.07 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $32.77 | 2023-2024 | Idacio |
| Strata Skin Sciences, INC. | $25.51 | 2022-2024 | Xtrac |
| Journey Medical Corporation | $20.34 | 2019-2022 | |
| Organon LLC | $19.52 | 2025 | |
| Sun Pharmaceutical Industries INC. | $17.17 | 2024 | |
| Verrica Pharmaceuticals INC. | $16.87 | 2024 | Ycanth |
| Genzyme Corporation | $15.50 | 2024 | |
| Celgene Corporation | $14.85 | 2019 | |
| Dermavant Sciences, INC. | $14.81 | 2024 | Vtama |
| Mylan Pharmaceuticals INC. | $12.96 | 2019 | |
| Incyte Corporation | $12.48 | 2022 | |
| Merck Sharp & Dohme LLC | $12.26 | 2019 | |
| Aclaris Therapeutics, INC. | $11.63 | 2019 | |
| Promius Pharma LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Warmuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.